Cargando…

Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials

BACKGROUND: Ramucirumab is a widely used cancer drug having gained six regulatory approvals in various advanced solid tumors. Thus, assessing the risk-benefit profile of such a commonly used drug across multiple tumor types is necessary to inform clinical and reimbursement decisions. To objectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Effing, Sophie Marie Anne, Gyawali, Bishal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486320/ https://www.ncbi.nlm.nih.gov/pubmed/32954236 http://dx.doi.org/10.1016/j.eclinm.2020.100458

Ejemplares similares

Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
por: Cao, Junning, et al.
Publicado: (2017)

Assessing the benefits and harms of direct oral anticoagulants in patients with cancer for the prophylaxis and treatment of venous thromboembolism: a systematic review and meta-analysis
por: Desai, Aakash, et al.
Publicado: (2020)

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
por: Cobain, Erin F., et al.
Publicado: (2021)

Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020
por: Jenei, Kristina, et al.
Publicado: (2023)

Oncology training programmes for general practitioners: a scoping review
por: Gyawali, Bishal, et al.
Publicado: (2021)

Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors
por: Olszanski, Anthony J., et al.
Publicado: (2016)

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
por: van der Heijden, Michiel S., et al.
Publicado: (2022)

Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis
por: Strzebonska, Karolina, et al.
Publicado: (2022)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

Lack of pharmacokinetic drug–drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors
por: Chow, Laura Q. M., et al.
Publicado: (2016)

Ramucirumab: A New Therapy for Advanced Gastric Cancer
por: Oholendt, Andrea Landgraf, et al.
Publicado: (2015)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

Endpoints used in phase III randomized controlled trials of treatment options for COVID-19
por: Desai, Aakash, et al.
Publicado: (2020)

Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
por: Llovet, Josep M., et al.
Publicado: (2022)

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
por: ElHalawani, Hesham, et al.
Publicado: (2015)

Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma
por: Nishioka, Naoya, et al.
Publicado: (2018)

Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries
por: Gyawali, Bishal, et al.
Publicado: (2016)

Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis
por: Gyawali, Bishal, et al.
Publicado: (2019)

Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer
por: Cooper, Maryann R, et al.
Publicado: (2016)

Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma
por: Kamachi, Naoki, et al.
Publicado: (2021)

Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis
por: Strzebonska, Karolina, et al.
Publicado: (2021)

The OlympiAD trial: who won the gold?
por: Gyawali, Bishal
Publicado: (2017)

Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
por: Xiao, Bingkun, et al.
Publicado: (2018)

Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials
por: Tang, Lingxue, et al.
Publicado: (2022)

Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
por: de Wit, Ronald, et al.
Publicado: (2022)

Efficacy and safety of ramucirumab treatment in patients with advanced colorectal cancer: A protocol for systematic review and meta analysis
por: Ju, Man, et al.
Publicado: (2020)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Ramucirumab: preclinical research and clinical development
por: Aprile, Giuseppe, et al.
Publicado: (2014)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer
por: Sorokin, Maxim, et al.
Publicado: (2020)

Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta‐analysis
por: Zhang, Tian‐yi, et al.
Publicado: (2023)

Ramucirumab in Indian Patients with Advanced Gastric Cancer—Does Borderline Performance Status and Heavy Burden of Disease in Real World Practice Impact Clinical Benefit?
por: Ramaswamy, Anant, et al.
Publicado: (2021)

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer
por: Kawai, Sadayuki, et al.
Publicado: (2020)

Bronchobiliary fistula after ramucirumab treatment for advanced gastric cancer: A case report
por: Kim, Hong-Beum, et al.
Publicado: (2019)

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
por: Zhu, Andrew X., et al.
Publicado: (2021)

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma
por: Sugimoto, Rie, et al.
Publicado: (2022)

Intention to probe into the colonoscopy trial: Is it the procedure or the trial that failed?
por: Knopf, Kevin B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tkbjvm94qpb39ka6dgcpj6oqkn